Multiple Sclerosis Clinical Trial
Official title:
Functional Electrical Stimulation to Treat Foot Drop in People With Multiple Sclerosis
People with multiple sclerosis (MS) often suffer from foot drop, which impairs their walking ability. Foot drop is the inability to lift the foot during the swing phase of walking. The purpose of this study is to find out if electrical stimulation of the leg, using the Bioness L300 Foot Drop System, can be used to treat foot drop in people with MS. It is expected that using this system will reduce foot drop, and therefore improve walking ability, particularly in the areas of speed, strength, balance and falls.
Due to damage of their central nervous system, people with multiple sclerosis (MS) often
develop abnormal gait. One common problem is the inability to lift the foot during the swing
phase; this is called foot drop, and is caused by loss of ankle dorsiflexor strength and
spasticity of the ankle plantarflexors. Foot drop leads to imbalance and increased risk of
falling, due to the foot dragging on the ground. Treating foot drop can result in improved
gait, faster walking speeds, improved balance and reduced risk of falling.
Functional electrical stimulation (FES) stimulates either the superficial or deep branches
of the common peroneal nerve. This stimulation leads to contraction of the ankle
dorsiflexors and evertors, which causes dorsiflexion and eversion of the foot, resulting in
the stepping motion of lifting the toes toward the shin. This reduces foot drop, allowing
the user to regain a more natural stepping pattern; it also reduces spasticity, strengthens
muscles and increases joint range of motion.
The Bioness L300 Foot Drop System consists of three components: a leg cuff worn just below
the knee, which provides electrical stimulation to the common peroneal nerve; a gait sensor
attached to the shoe, which detects which stage of the gait cycle the foot is in; and a
control unit, which is used to adjust the level of stimulation received. These three
components communicate wirelessly with each other, so that the electrical stimulation is
applied at the appropriate time during each gait cycle.
The study physician will set up the system to optimize stimulation according to each
participant's gait and needs, and participants will use the system for 12 weeks. There will
be an initial four week adaptation period for using the system. During this first four weeks
participants will gradually increase their use of the system until they are using it all
day, which will allow their muscles to adjust to the electrical stimulation and help prevent
fatigue. During the remaining eight weeks participants will be instructed to use the system
all day, when walking at home and in the community.
Participants will have their walking speed and heart rate measured during a 10-metre
straight line walking test and a 4-minute figure-8 walking test at baseline, weeks 4, 8 and
12. Participants will perform both tests at each time point without and with the L300 Foot
Drop System. Participant satisfaction will be assessed at the end of the 12-week trial.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT02845635 -
MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis
|